Pfizer - Recruiting 18 years or older. - Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Of Fulvestrant (Faslodex?) With Or Without PD-0332991 (Palbociclib) +/- Goserelin In Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy.
Japan Breast Cancer Research Group - Recruiting 20 years to 75 years. - Bevacizumab Plus Paclitaxel Optimization Study With Interventional Maintenance Endocrine Therapy in Advanced or Metastatic ER-positive HER2-negative Breast Cancer -BOOSTER Trial, a Multicenter Randomized Phase II Study-.
Alliance for Clinical Trials in Oncology - Recruiting 18 years or older. - Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study.
Genentech - Recruiting 18 years or older. - A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination With Either Docetaxel or Paclitaxel in Patients With HER2-Negative, Locally Advanced or Metastatic Breast Cancer.
Novartis - Recruiting 18 years or older. - A Randomized, Double-blind, Placebo Controlled, Phase II/III Study of BKM120 Plus Paclitaxel in Patients With HER2 Negative Inoperable Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Pathway Activation..
Celgene Corporation - Recruiting 18 years or older. - A Phase 2/3, Multi-center, Open-label, Randomized Study of Weekly Nab-paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to the Combination of Gemcitabine and Carboplatin, as First-line Treatment in Female Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer.
nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects; Carboplatin AUC 2; gemcitabine 1000 mg
Roswell Park Cancer Institute - Recruiting 50 years or older. - Phase II Trial of Single Fraction Radiation Therapy (SFRT) at Roswell Park Cancer Institute for Select Patients With Early Stage Breast Cancer.
Tesaro, Inc. - Recruiting 18 years or older. - A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients.
Medica Scientia Innovation Research - Recruiting 18 years or older. - A Phase IIa Prospective, Multicenter, Open and Not Controlled of the Efficacy and Tolerability on the First Line Treatment With Eribulin as a Unic Agent on Patients With HER2 Negative Metastatic Breast Cancer Previously Treated With Taxanes.
Synta Pharmaceuticals Corp. - Recruiting 18 years or older. - An Open Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib(STA-9090) Monotherapy in Women With Previously Untreated Metastatic HER2 Positive or Triple Negative Breast Cancer.
Novartis - Recruiting 18 years or older. - A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer.
Novartis - Recruiting N/A or older. - A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease.
National Cancer Institute (NCI) - Recruiting 18 years or older. - A PHASE III, RANDOMIZED CLINICAL TRIAL OF STANDARD ADJUVANT ENDOCRINE THERAPY +/-CHEMOTHERAPY IN PATIENTS WITH 1-3 POSITIVE NODES, HORMONE RECEPTOR-POSITIVE AND HER2-NEGATIVE BREAST CANCER WITH RECURRENCE SCORE (RS) OF 25 OR LESS. RXPONDER: A CLINICAL TRIAL RX FOR POSITIVE NODE, ENDOCRINE RESPONSIVE BREAST CANCER.
University of Ulm - Recruiting 18 years or older. - DETECT IV - A Multicenter Single Arm Phase II Study to Investigate the Clinical Efficacy of Everolimus in Combination With Endocrine Therapy in Postmenopausal Patients With Hormone-receptor Positive, HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells..
Everolimus in combination with standard endocrine therapy
Thomas Jefferson University - Recruiting 18 years or older. - An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer.
Medical University of Graz - Recruiting 18 years to 80 years. - Prospective Validation of Genomic Signatures to Predict Treatment Response in the Axillary Nodes After Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer.
University of Washington - Recruiting 18 years or older. - Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer.
veliparib; cisplatin; vinorelbine tartrate; laboratory biomarker analysis; pharmacological study
Novartis - Recruiting 18 years or older. - A Phase III Randomized, Double Blind Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative Locally Advanced or Metastatic Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
Washington University School of Medicine - Recruiting 18 years or older. - A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells.
Hellenic Oncology Research Group - Recruiting 18 years to 70 years. - Phase II, Open-label Non-randomized Trial to Investigate the Efficacy of Bevacizumab in Combination With Dose Dense Sequential Chemotherapy in the Neo-adjuvant Setting for HER2 Negative Breast Cancer Patients.
New York University School of Medicine - Recruiting 18 years or older. - Phase II Trial of Exemestane With Immunomodulatory Cyclophosphamide in ER and/or PR-positive and HER2/Neu Negative Metastatic Breast Cancer.
Asan Medical Center - Recruiting 20 years or older. - A Phase III, Open-Label, Prospective, Randomized, Multicenter, Neo-adjuvant Study of Chemotherapy Versus Endocrine Therapy in Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer.
Adriamycin+Cyclophosphamide>Docetaxel; GnRHa with Tamoxifen
National Cancer Institute (NCI) - Recruiting 18 years or older. - A Phase 1 Study With Dose Expansion of Dinaciclib (SCH 727965) in Combination With Epirubicin in Patients With Metastatic Triple Negative Breast Cancer.
UNICANCER - Recruiting 18 years or older. - A Phase II Trial Evaluating the Activity of Abiraterone Acetate Plus Prednisone in Patients With a Molecular Apocrine HER2-negative Locally Advanced or Metastatic Breast Cancer.
Novartis - Recruiting 18 years or older. - A Phase III Randomized, Double Blind, Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTOR Inhibitor Based Treatment.
M.D. Anderson Cancer Center - Recruiting 18 years or older. - Feasibility, Validation and Implementation of Genomic Testing for Chemotherapy and Endocrine Sensitivity of HER2 Negative Primary Invasive Breast Cancer (Clinical Stage I to III).
Fondazione Michelangelo - Recruiting 18 years or older. - Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With HER2-negative, ER and/or PgR Positive Metastatic Brest Cancer With Progressive Disease After First-line Therapy.
Asociaci¢n Oncosur - Recruiting 18 years or older. - Neurotoxicity Characterization Phase II Randomized Study of Nab-paclitaxel Versus Conventional Paclitaxel as First-line Therapy of Metastatic HER2-negative Breast Cancer..
Paclitaxel 80 mg/m2; Nab-paclitaxel 100 mg/m2 days 1, 8 and 15; Nab-paclitaxel 150 mg/m2 days 1, 8 and 15; Nab-paclitaxel 150 mg/m2 days 1 and 15
Heinrich-Heine University, Duesseldorf - Recruiting 18 years or older. - DETECT III - A Multicenter, Randomized, Phase III Study to Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients With Initially HER2-negative Metastatic Breast Cancer and HER2-positive Circulating Tumor Cells.
standard chemo- or endocrine therapy; standard chemo- or endocrine therapy + Lapatinib